Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Other Non-Current Assets (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Other Non-Current Assets readings, the most recent being $210000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 60.31% to $210000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $210000.0, a 60.31% increase, with the full-year FY2025 number at $210000.0, up 60.31% from a year prior.
  • Other Non-Current Assets hit $210000.0 in Q4 2025 for Avalo Therapeutics, roughly flat from $210000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.0 million in Q4 2021 to a low of $131000.0 in Q4 2022.
  • Median Other Non-Current Assets over the past 5 years was $140000.0 (2021), compared with a mean of $205000.0.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 86.9% in 2022 and later skyrocketed 60.31% in 2025.
  • Avalo Therapeutics' Other Non-Current Assets stood at $1.0 million in 2021, then tumbled by 86.9% to $131000.0 in 2022, then changed by 0.0% to $131000.0 in 2023, then changed by 0.0% to $131000.0 in 2024, then skyrocketed by 60.31% to $210000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $210000.0 (Q4 2025), $210000.0 (Q3 2025), and $210000.0 (Q2 2025) per Business Quant data.